Synthesis of BI 1584142 and BI 1810631 (Zongertinib), Two Potent HER2 Inhibitors, Labeled With Carbon-14 and With Deuterium
{{output}}
BI 1584142 (1) and BI 1810631 (2, zongertinib) are potent and selective HER2 tyrosine kinase inhibitors being developed for the treatment of non-small cell lung cancer. Carbon-14-labeled versions of these drug candidates were needed to study their absorption, ... ...
